BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2021. [PMID: 34173007 DOI: 10.1007/s00259-021-05475-0] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Chang WY, Tseng NC, Chen LY, Chang CW, Huang YY, Huang YT, Ou YC, Peng NJ. Comparison of the Detection Performance Between FAP and FDG PET/CT in Various Cancers: A Systemic Review and Meta-analysis. Clin Nucl Med 2023;48:132-42. [PMID: 36607362 DOI: 10.1097/RLU.0000000000004438] [Reference Citation Analysis]
2 Huang D, Wu J, Zhong H, Li Y, Han Y, He Y, Chen Y, Lin S, Pang H. [(68)Ga]Ga-FAPI PET for the evaluation of digestive system tumors: systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2023;50:908-20. [PMID: 36326867 DOI: 10.1007/s00259-022-06021-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Wang Y, Luo W, Li Y. [(68)Ga]Ga-FAPI-04 PET MRI/CT in the evaluation of gastric carcinomas compared with [(18)F]-FDG PET MRI/CT: a meta-analysis. Eur J Med Res 2023;28:34. [PMID: 36653862 DOI: 10.1186/s40001-023-00997-9] [Reference Citation Analysis]
4 Cheng Z, Wang S, Xu S, Du B, Li X, Li Y. FAPI PET/CT in Diagnostic and Treatment Management of Colorectal Cancer: Review of Current Research Status. J Clin Med 2023;12. [PMID: 36675506 DOI: 10.3390/jcm12020577] [Reference Citation Analysis]
5 Wei Y, Sun Y, Liu J, Zhang G, Qin X, Xu S, Wang S, Tao Y, Pei J, Yu J. Early detection of radiation-induced myocardial damage by [(18)F]AlF-NOTA-FAPI-04 PET/CT imaging. Eur J Nucl Med Mol Imaging 2023;50:453-64. [PMID: 36121463 DOI: 10.1007/s00259-022-05962-y] [Reference Citation Analysis]
6 Kirienko M, Erba PA, Chiti A, Sollini M. Hybrid PET/MRI in Infection and Inflammation: An Update About the Latest Available Literature Evidence. Semin Nucl Med 2023;53:107-24. [PMID: 36369091 DOI: 10.1053/j.semnuclmed.2022.10.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Schmidkonz C, Kuwert T, Atzinger A, Cordes M, Schett G, Ramming A, Götz T. Fibroblast Activation Protein Inhibitor Imaging in Nonmalignant Diseases: A New Perspective for Molecular Imaging. J Nucl Med 2022;63:1786-92. [PMID: 36109182 DOI: 10.2967/jnumed.122.264205] [Reference Citation Analysis]
8 van den Hoven AF, Keijsers RGM, Lam MGEH, Glaudemans AWJM, Verburg FA, Vogel WV, Lavalaye J. Current research topics in FAPI theranostics: a bibliometric analysis. Eur J Nucl Med Mol Imaging 2022. [DOI: 10.1007/s00259-022-06052-9] [Reference Citation Analysis]
9 Peltier A, Seban RD, Buvat I, Bidard FC, Mechta-Grigoriou F. Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging. Semin Cancer Biol 2022;86:262-72. [PMID: 35489628 DOI: 10.1016/j.semcancer.2022.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
10 Greifenstein L, Kramer CS, Moon ES, Rösch F, Klega A, Landvogt C, Müller C, Baum RP. From Automated Synthesis to In Vivo Application in Multiple Types of Cancer-Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi. Pharmaceuticals (Basel) 2022;15:1000. [PMID: 36015148 DOI: 10.3390/ph15081000] [Reference Citation Analysis]
11 Dondi F, Albano D, Treglia G, Bertagna F. Emerging Role of FAPI PET Imaging for the Assessment of Benign Bone and Joint Diseases. JCM 2022;11:4514. [DOI: 10.3390/jcm11154514] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Raju S, Shukla J, Kumar R. Fibroblast Activation Protein Inhibitor Theranostics. PET Clin 2022;17:453-64. [PMID: 35717101 DOI: 10.1016/j.cpet.2022.03.005] [Reference Citation Analysis]
13 Krarup MMK, Fischer BM, Christensen TN. New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. Semin Nucl Med 2022:S0001-2998(22)00052-6. [PMID: 35752465 DOI: 10.1053/j.semnuclmed.2022.05.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, Ungewiss J, Paschke M, Haase C, von Hacht JL, Kwan T, Lin KK, Lenore J, Harding TC, Xiao J, Simmons AD, Mohan AM, Beindorff N, Reineke U, Smerling C, Osterkamp F. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35608703 DOI: 10.1007/s00259-022-05842-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Rosenkrans ZT, Massey CF, Bernau K, Ferreira CA, Jeffery JJ, Schulte JJ, Moore M, Valla F, Batterton JM, Drake CR, McMillan AB, Sandbo N, Pirasteh A, Hernandez R. [68 Ga]Ga-FAPI-46 PET for non-invasive detection of pulmonary fibrosis disease activity. Eur J Nucl Med Mol Imaging 2022. [PMID: 35556159 DOI: 10.1007/s00259-022-05814-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Balma M, Liberini V, Racca M, Laudicella R, Bauckneht M, Buschiazzo A, Nicolotti DG, Peano S, Bianchi A, Albano G, Quartuccio N, Abgral R, Morbelli SD, D'Alessandria C, Terreno E, Huellner MW, Papaleo A, Deandreis D. Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review. Front Med (Lausanne) 2022;9:881551. [PMID: 35492341 DOI: 10.3389/fmed.2022.881551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Roustaei H, Kiamanesh Z, Askari E, Sadeghi R, Aryana K, Treglia G. Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents? Contrast Media Mol Imaging 2022;2022:3948873. [PMID: 35280710 DOI: 10.1155/2022/3948873] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Wang S, Huang Q, Dong K, Qin C, Wen G. Double Trap Escape: Omental Nodular Hyperplasia Misdiagnosed as Metastasis by 18F-FDG PET/CT and 68Ga-FAPI PET/MRI in a Patient With Gastric Adenocarcinoma. Clin Nucl Med 2022;Publish Ahead of Print. [DOI: 10.1097/rlu.0000000000004192] [Reference Citation Analysis]
19 Kersting D, Settelmeier S, Mavroeidi IA, Herrmann K, Seifert R, Rischpler C. Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology. Int J Mol Sci 2022;23:3802. [PMID: 35409161 DOI: 10.3390/ijms23073802] [Reference Citation Analysis]
20 Fiz F, Masci C, Costa G, Sollini M, Chiti A, Ieva F, Torzilli G, Viganò L. PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05765-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Younis MH, Malih S, Lan X, Rasaee MJ, Cai W. Enhancing fibroblast activation protein (FAP)-targeted radionuclide therapy with albumin binding, and beyond. Eur J Nucl Med Mol Imaging 2022. [PMID: 35332379 DOI: 10.1007/s00259-022-05766-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Sollini M, Hurle R, Rodari M, Chiti A, Lazzeri M. Things are because we see them (O. Wilde): new radiopharmaceuticals for nuclear medicine imaging. Eur J Nucl Med Mol Imaging 2022. [PMID: 35316385 DOI: 10.1007/s00259-022-05768-y] [Reference Citation Analysis]
23 Li M, Younis MH, Zhang Y, Cai W, Lan X. Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond. Eur J Nucl Med Mol Imaging. [DOI: 10.1007/s00259-022-05706-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
24 Yang T, Ma L, Hou H, Gao F, Tao W. FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors. Front Oncol 2021;11:797960. [PMID: 35059319 DOI: 10.3389/fonc.2021.797960] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Umesh A, Pranay K, Pandey RC, Gupta MK. Evidence mapping and review of long-COVID and its underlying pathophysiological mechanism. Infection 2022;50:1053-66. [PMID: 35489015 DOI: 10.1007/s15010-022-01835-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management. Front Oncol 2021;11:758958. [PMID: 34858834 DOI: 10.3389/fonc.2021.758958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
27 Lindner T, Giesel FL, Kratochwil C, Serfling SE. Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers (Basel) 2021;13:5744. [PMID: 34830898 DOI: 10.3390/cancers13225744] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
28 Al Tabaa Y, Bailly C, Kanoun S. FDG-PET/CT in Lymphoma: Where Do We Go Now? Cancers (Basel) 2021;13:5222. [PMID: 34680370 DOI: 10.3390/cancers13205222] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R. Head-to-Head Comparison of Fibroblast Activation Protein Inhibitors (FAPI) Radiotracers versus [18F]F-FDG in Oncology: A Systematic Review. Int J Mol Sci 2021;22:11192. [PMID: 34681850 DOI: 10.3390/ijms222011192] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
30 Zhang X, Chen L, Jiang H, He X, Feng L, Ni M, Ma M, Wang J, Zhang T, Wu S, Zhou R, Jin C, Zhang K, Qian W, Chen Z, Zhuo C, Zhang H, Tian M. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2021. [PMID: 34651227 DOI: 10.1007/s00259-021-05572-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
31 Liberini V, Mariniello A, Righi L, Capozza M, Delcuratolo MD, Terreno E, Farsad M, Volante M, Novello S, Deandreis D. NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images. Cancers (Basel) 2021;13:4543. [PMID: 34572771 DOI: 10.3390/cancers13184543] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
32 Xin L, Gao J, Zheng Z, Chen Y, Lv S, Zhao Z, Yu C, Yang X, Zhang R. Fibroblast Activation Protein-α as a Target in the Bench-to-Bedside Diagnosis and Treatment of Tumors: A Narrative Review. Front Oncol 2021;11:648187. [PMID: 34490078 DOI: 10.3389/fonc.2021.648187] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
33 Evangelista L, Ekmekcioglu O, Kunikowska J. Gender balance in the editorial board of nuclear medicine journals. Eur J Nucl Med Mol Imaging 2021. [PMID: 34379144 DOI: 10.1007/s00259-021-05491-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]